

# Santiago Grau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428486/publications.pdf>

Version: 2024-02-01

66  
papers

1,322  
citations

566801

15  
h-index

377514

34  
g-index

71  
all docs

71  
docs citations

71  
times ranked

1716  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review. Expert Review of Anti-Infective Therapy, 2022, 20, 179-197.  | 2.0 | 9         |
| 2  | COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing. Vaccines, 2022, 10, 594.  | 2.1 | 4         |
| 3  | Ceftaroline removal during plasmapheresis. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2022, 40, 216-217.   | 0.2 | 0         |
| 4  | Therapeutic drug monitoring of colistin in plasma and cerebrospinal fluid in meningoventriculitis caused by a carbapenem-resistant Enterobacter cloacae. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2022, 40, 277-278. | 0.2 | 0         |
| 5  | The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain. Mycoses, 2021, 64, 66-77.              | 1.8 | 11        |
| 6  | Antibiotic consumption trends among acute care hospitals in Catalonia (2008-2016): impact of different adjustments on the results. Expert Review of Anti-Infective Therapy, 2021, 19, 245-251.  | 2.0 | 4         |
| 7  | Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. Antibiotics, 2021, 10, 132.  | 1.5 | 56        |
| 8  | Osteoarticular Cryptococcosis Successfully Treated with High-Dose Liposomal Amphotericin B Followed by Oral Fluconazole. Infection and Drug Resistance, 2021, Volume 14, 719-722.   | 1.1 | 5         |
| 9  | A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. Therapeutic Drug Monitoring, 2021, 43, 747-755.     | 1.0 | 3         |
| 10 | Therapeutic drug monitoring of colistin in plasma and cerebrospinal fluid in meningoventriculitis caused by a carbapenem-resistant Enterobacter cloacae. Enfermedades Infecciosas Y Microbiología Clínica, 2021, , .                        | 0.3 | 0         |
| 11 | Risk Factors for Amoxicillin-Clavulanate Resistance in Community-Onset Urinary Tract Infections Caused by Escherichia coli or Klebsiella pneumoniae: The Role of Prior Exposure to Fluoroquinolones. Antibiotics, 2021, 10, 582.            | 1.5 | 8         |
| 12 | Nebulized Micafungin Treatment for <i>Scopulariopsis</i> / <i>Microascus</i> Tracheobronchitis in Lung Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2021, 65, .  | 1.4 | 3         |
| 13 | Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients. Antibiotics, 2021, 10, 666.   | 1.5 | 1         |
| 14 | Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia: A Cohort Study. Antibiotics, 2021, 10, 716.  | 1.5 | 5         |
| 15 | Reconstituted mRNA COVID-19 vaccines may maintain stability after continuous movement. Clinical Microbiology and Infection, 2021, 27, 1698.e1-1698.e4.  | 2.8 | 6         |
| 16 | Reimbursement of innovative pharmaceuticals in English and Spanish hospitals- The example of isavuconazole. Mycoses, 2021, 64, 1213-1222.   | 1.8 | 2         |
| 17 | Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. Antibiotics, 2021, 10, 943.  | 1.5 | 36        |
| 18 | Impact of Generic Entry on Hospital Antimicrobial Use: A Retrospective Quasi-Experimental Interrupted Time Series Analysis. Antibiotics, 2021, 10, 1149.  | 1.5 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality. <i>Antibiotics</i> , 2021, 10, 1296.  | 1.5 | 4         |
| 20 | Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 214-222.                | 0.8 | 3         |
| 21 | Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates in a hollow-fiber infection model. <i>Scientific Reports</i> , 2021, 11, 22178.                                       | 1.6 | 6         |
| 22 | Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 752879.                | 1.6 | 1         |
| 23 | Ivermectin: a pathway out of the pandemic or another dead end?. <i>Expert Review of Anti-Infective Therapy</i> , 2021, , 1-3.  | 2.0 | 1         |
| 24 | Personalized antimicrobial therapy in critical and elderly patients.. <i>Farmacia Hospitalaria</i> , 2021, 45, 64-76.  | 0.6 | 0         |
| 25 | Effects of the extracorporeal membrane oxygenation circuit on plasma levels of ceftolozane. <i>Perfusion (United Kingdom)</i> , 2020, 35, 267-270.   | 0.5 | 4         |
| 26 | Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. <i>Journal of Medical Economics</i> , 2020, 23, 148-155.  | 1.0 | 1         |
| 27 | Which type of bone releases the most vancomycin? Comparison of spongy bone, cortical powder and cortico-spongy bone. <i>Cell and Tissue Banking</i> , 2020, 21, 131-137.   | 0.5 | 1         |
| 28 | Impact of changes in the WHO's 2019 update of DDDs on the measurement of adult hospital antibacterial consumption in Catalonia (Spain), 2008-18. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa079.   | 0.9 | 2         |
| 29 | Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury. <i>Antibiotics</i> , 2020, 9, 887.  | 1.5 | 11        |
| 30 | Strong opioid consumption and its correlation with pain intensity and inpatient complexity. A 6-year analysis in a tertiary hospital. <i>European Journal of Pain</i> , 2020, 24, 1151-1159.   | 1.4 | 0         |
| 31 | Risk Factors for Mortality among Patients with <i>Pseudomonas aeruginosa</i> Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?. <i>Journal of Clinical Medicine</i> , 2020, 9, 514.  | 1.0 | 27        |
| 32 | Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child Pugh B or C Liver Disease: A Case-Control Retrospective Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 151-163. | 1.8 | 3         |
| 33 | Widespread increase of empirical carbapenem use in acute care hospitals in Catalonia, Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 36-40.  | 0.3 | 10        |
| 34 | Colistin for the treatment of urinary tract infections caused by extremely drug-resistant <i>Pseudomonas aeruginosa</i> : Dose is critical. <i>Journal of Infection</i> , 2019, 79, 253-261.   | 1.7 | 28        |
| 35 | Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Infections. <i>Clinical Microbiology Reviews</i> , 2019, 32, .  | 5.7 | 489       |
| 36 | Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3268-3273.                       | 1.3 | 12        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?. <i>Molecules</i> , 2019, 24, 530.  | 1.7 | 7         |
| 38 | Successful ceftolozane-azobactam rescue therapy in a child with endocarditis caused by multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Paediatrics and Child Health</i> , 2019, 55, 985-987.   | 0.4 | 14        |
| 39 | Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 732-739.  | 1.0 | 17        |
| 40 | Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 376-382.   | 1.0 | 4         |
| 41 | A Before-and-After Study of the Effectiveness of an Antimicrobial Stewardship Program in Critical Care. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .   | 1.4 | 37        |
| 42 | Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. <i>Germs</i> , 2018, 8, 109-112.   | 0.5 | 7         |
| 43 | Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent <i>Clostridium difficile</i> Infection in High-Risk Patients in Spain. <i>Advances in Therapy</i> , 2018, 35, 1920-1934.       | 1.3 | 17        |
| 44 | Extremely high levels of vancomycin can cause severe renal toxicity. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1027-1030.  | 1.1 | 21        |
| 45 | Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 39-47. | 0.7 | 5         |
| 46 | Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. <i>Advances in Therapy</i> , 2017, 34, 2104-2119.  | 1.3 | 9         |
| 47 | Community-acquired pneumonia caused by methicillin-resistant <i>Staphylococcus aureus</i> in critically-ill patients: systematic review. <i>Farmacia Hospitalaria</i> , 2017, 41, 187-203.   | 0.6 | 4         |
| 48 | Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. <i>Drug Design, Development and Therapy</i> , 2016, Volume11, 65-82.  | 2.0 | 18        |
| 49 | Can we guarantee less nephrotoxicity when vancomycin is administered by continuous infusion?. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 116-117.  | 1.1 | 5         |
| 50 | The Delphi method applied to fungal infection: There is still some way to go. <i>Revista Iberoamericana De Micologia</i> , 2016, 33, 185-186.  | 0.4 | 0         |
| 51 | What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 696-702.   | 1.3 | 37        |
| 52 | Severe thrombocytopenia caused by linezolid poisoning in an underweight critically ill patient with renal impairment treated with the recommended doses. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 213-214.                              | 0.3 | 4         |
| 53 | Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008-2013. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 137-144.  | 2.0 | 10        |
| 54 | Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 652-654.  | 0.3 | 8         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Patient risk factors for developing a drug-related problem in a cardiology ward. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 9.   | 0.9 | 34        |
| 56 | The impact of <i>Clostridium difficile</i> infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. <i>International Journal of Infectious Diseases</i> , 2015, 36, 31-38.                         | 1.5 | 23        |
| 57 | Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections. <i>Journal of Infection</i> , 2015, 71, 604-607.   | 1.7 | 16        |
| 58 | Antifungal therapeutic drug monitoring: When, how, and why. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 295-297.   | 0.3 | 4         |
| 59 | Comment on: Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3168-3168.   | 1.3 | 2         |
| 60 | Pharmacokinetics/pharmacodynamics of micafungin in a surgical critically ill patient during extracorporeal carbon dioxide removal and continuous renal replacement therapy. <i>Journal of Critical Care</i> , 2015, 30, 1129-1130.     | 1.0 | 6         |
| 61 | Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia, Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 70, 1193-7.   | 1.3 | 11        |
| 62 | Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1624-1632. | 1.3 | 35        |
| 63 | Comment on: Glycopeptide use is associated with increased mortality in <i>Enterococcus faecalis</i> bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3165-3166.   | 1.3 | 3         |
| 64 | How to measure and monitor antimicrobial consumption and resistance. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 16-24.  | 0.3 | 34        |
| 65 | Antibiotic consumption at 46 VINCat hospitals from 2007 to 2009, stratified by hospital size and clinical services. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2012, 30, 43-51.   | 0.3 | 10        |
| 66 | Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR <i>Pseudomonas aeruginosa</i> Infections: An Observational Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 0, , .   | 0.6 | 2         |